Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | USP6 |
| Gene Name: | USP6 |
| Protein Full Name: | Ubiquitin carboxyl-terminal hydrolase 6 |
| Alias: | Deubiquitinating enzyme 6; HRP1; Oncogene; Proto-oncogene TRE-2; TRE17; TRE2; Tre-2; Tre-2 oncogene; Ubiquitin specific peptidase 6; Ubiquitin thioesterase 6; Ubiquitin-specific-processing protease 6 |
| Mass (Da): | 158658 |
| Number AA: | 1406 |
| UniProt ID: | P35125 |
| Locus ID: | 9098 |
| COSMIC ID: | USP6 |
| Gene location on chromosome: | 17p13 |
| Cancer protein type: | OP |
| Effect of cancer mutation on protein: | GAIN |
| Effect of active protein on cancer: | PROMOTES |
| Number of cancer specimens: | 20357 |
| Percent of cancer specimens with mutations: | 0.66 |
| Deregulated in translocations: | USP6 fusion genes are formed by juxtaposition of USP6 coding sequences to the promoter regions of several partner genes, which lead to USP6 transcriptional upregulation. There is no fusion protein. THRAP3 -USP6 in t(1;17)(p34;p13) ZNF9 -USP6 in t(3;17)(q2 |
| Normal role description: | USP6 romotes plasma membrane localization of ARF6 and selectively regulates ARF6-dependent endocytic protein trafficking. Is able to initiate tumorigenesis by inducing the production of matrix metalloproteinases following NF-kappa-B activation. |